Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Otsuka’s Alzheimers agitation drug hits the mark

Otsuka’s Alzheimer’s agitation drug hits the mark

Otsuka has reported positive phase 3 results with a drug intended to calm agitation in patients with Alzheimer’s disease. ... It may seem a minor victory after the failure of Biogen’s aducanumab in Alzheimer’s disease last week – further

Latest news

  • Undeterred by aducanumab failure, Eisai and Biogen plough on Undeterred by aducanumab failure, Eisai and Biogen plough on

    Investors sceptical, though mechanism different. Mere hours after reporting the failure of aducanumab in Alzheimer’s disease, Eisai has cued up a phase 3 trial of BAN2401, another amyloid-targeted drug. ... The idea that blocking the formation of the

  • Biogen and Eisai pull plug on Alzheimer’s drug Biogen and Eisai pull plug on Alzheimers drug

    Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, chief executive at Biogen. ... pipeline of potential therapies in Alzheimer’s

  • Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022 Biogen, Eisai cue up BAN2401 readout in Alzheimers in 2022

    Also considering a trial in preclinical Alzheimer’s subjects. Biogen and Eisai spent the latter half of 2018 defending phase 2b results with their Alzheimer’s disease candidate BAN2401 against sceptics, ... s disease, while BAN2401 binds to and

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    overcome disappointments seen in neurology, most especially in Alzheimer’s disease. ... Its initial focus is on frontotemporal dementia (AL001 entering phase 1 trials in September) and Alzheimer’s disease, AL002 also entering phase 1 in December.

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    Good news after Alzheimer's failure. Roche saw a decline in its European sales last year as biosimilars started to bite its blockbuster biologic drugs, but strong growth for new products ... The buoyant performance will help numb the pain of Roche’s

More from news
Approximately 50 fully matching, plus 306 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    on earth have spent billions on Alzheimer’s disease. ... And there is scope to improve the lives of Alzheimer’s patients without slowing the progression of the disease, for example by hitting targets that improve cognition.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    A phase I dose escalation study of AL002 for patients with Alzheimer’s disease, as part of a global strategic partnership with AbbVie, is ongoing. ... Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders,

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimers disease – is Europe prepared if a breakthrough treatment becomes available?

    Currently, there is no Alzheimer’s disease- modifying treatment available but there are several therapies in development. ... If appropriate, they would be referred to treatment, which would reduce the risk of progression from MCI to manifest dementia

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s.The anti-Parkinson medications available primarily promote dopamine levels in the brain to compensate for the loss of ... The design of such neuroprotective

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Option exercise (2 options). 640.

More from intelligence
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    the US suffer from Alzheimer’s disease, and  795, 000  Americans suffer from strokes annually. ... It’s a little bit like it was in the old days of buying IBM computers,” he says.

  • Synergy Vision

    Alzheimer's and Brain Awareness Month. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia.

  • Alzheimer's and Brain Awareness Month

    June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s

More from PMHub
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics